Welcome to our dedicated page for Incannex Healthcare SEC filings (Ticker: IXHL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Incannex Healthcare Inc. filings document material-event disclosures for a Nasdaq-listed clinical-stage biopharmaceutical company. Recent Form 8-K reports furnish Regulation FD press releases tied to clinical program updates, research partnerships, capital actions and public-company status matters.
The filing record also discloses security and governance matters, including common stock registered on The Nasdaq Stock Market LLC, emerging growth company status, a certificate amendment effecting a 1-for-30 reverse stock split, Nasdaq minimum bid price compliance and capital-structure disclosures. Other material-event filings cover agreement termination, shareholder-rights modifications and related corporate actions.
Incannex Healthcare (NASDAQ: IXHL), an emerging growth company, announced the appointment of Dr. Douglas B. Kirsch to its Clinical Advisory Board on June 24, 2025, specifically to support its Obstructive Sleep Apnea program.
Key details from the 8-K filing:
- The company is listed on The Nasdaq Stock Market with common stock at $0.0001 par value per share
- Headquartered in Norwest, NSW, Australia
- Joel Latham serves as Chief Executive Officer and President
- The company has elected emerging growth company status
- The appointment represents a strategic expansion of expertise in sleep medicine, potentially strengthening the company's clinical development programs
This strategic addition to the advisory board signals Incannex's continued focus on advancing its sleep apnea therapeutic programs and enhancing its clinical development capabilities.